Harnessing the natural control mechanisms of the immune system
MiroBio’s mission is to develop novel, best-in-class therapeutics that bring significant benefits to patients suffering from a range of auto-immune diseases. MiroBio’s medicines will activate natural mechanisms to regain control of over-active immune responses triggering these diseases.
CEO Dr Carolin Barth
Advent Contact Shahzad Malik
Exited Investments
Gilead Sciences to Acquire Mirobio
Press Release. Acquisition Provides Gilead with MiroBio’s Pipeline of Immune Checkpoint Agonists and Proprietary Discovery Platform MiroBio’s Scientific Approach to Restoring Immune Balance for the Treatment of Autoimmune Diseases…
Read More
MiroBio Continues Expansion of Executive Leadership Team with Key Appointments to Advance Development of Checkpoint Agonist Antibodies for Autoimmune Disease
Press Release. Sanjay Keswani, MBBS, FRCP to join company as Chief Medical Officer bringing extensive experience in drug development and life sciences leadership Lynne Murray, Ph.D., MBA appointed as…
Read More
Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company Focused on Checkpoint Agonist Antibodies
Press Release. Former Novartis executive to lead emerging biotech with a novel precision approach to autoimmune disease, supported by recent senior appointments MiroBio is exclusively focused on…
Read More
